AirXpanders, based in Palo Alto, Calif., develops AeroForm, an injection-free, patient-controlled tissue-expansion system for breast reconstruction after mastectomy. The company is focused on completing a U.S. clinical trial for the technology and pursuing 510(k) clearance in the United States. It plans to use new funds to finish the clinical trial and implement semi-automation into AeroForm manufacturing to increase throughput. Outside the U.S., AirXpanders intends a limited market release in Australia following TGA approval and will conduct a key opinion leader assessment in Europe. The company is led by president and CEO Scott Dodson and is backed by Vivo Ventures, GBS Venture Partners, Prolog Ventures, Heron Capital and Shalon Ventures. AirXpanders, based in Palo Alto, CA, develops technology to address unmet needs for patients requiring tissue expansion for breast reconstruction surgery. Its core product is the AeroForm Patient‑Controlled Tissue Expander System, a self‑contained expander implanted in the same manner as a traditional saline expander and operated via a small handheld wireless remote. The expander contains a lipstick‑sized carbon‑dioxide reservoir that gradually releases CO2 through an internal valve, eliminating the need for invasive weekly saline injections. The company secured $10M in Series D financing to advance its regulatory and commercial plans. Proceeds will be used to complete an ongoing IDE study in the U.S., obtain a CE Mark, and execute market launches in the U.S., Europe and Australia following clearance. The IDE study results will be used to support a 510(k) application in the U.S.; the company is led by President and CEO Scott Dodson.

Total raised

$17M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Apr 2014